Financial Performance - Net profit attributable to shareholders decreased by 20.80% to CNY 11,731,517.27 for the year-to-date period[15] - Operating income for the year-to-date period decreased by 13.63% to CNY 96,125,595.93 compared to the same period last year[15] - Cash flow from operating activities decreased by 47.85% to CNY 9,041,300.56 compared to the same period last year[15] - Operating income for Q3 2022 increased by 8.95% to CNY 36,725,823.02 compared to Q3 2021[15] - Total operating revenue for Q3 2022 reached ¥36,725,823.02, an increase from ¥33,708,486.57 in Q3 2021, representing an increase of approximately 8.9% year-over-year[49] - Net profit for Q3 2022 was ¥3,887,300.91, up from ¥3,360,055.59 in Q3 2021, reflecting a growth of approximately 15.7% year-over-year[51] - The company’s total comprehensive income for the first nine months of 2022 was CNY 13,238,039, compared to CNY 15,830,795 in the same period of 2021[56] Assets and Liabilities - Total assets increased by 36.94% to CNY 406,038,834.29 compared to the end of the previous year[15] - Total current assets increased to CNY 131,543,220.47 as of September 30, 2022, up from CNY 86,677,798.07 on December 31, 2021, representing a growth of approximately 51.7%[41] - Non-current assets totaled CNY 274,495,613.82 as of September 30, 2022, up from CNY 209,825,087.39 on December 31, 2021, reflecting a growth of approximately 30.8%[42] - Total liabilities decreased to CNY 51,117,193.01 as of September 30, 2022, down from CNY 83,252,251.30 on December 31, 2021, a reduction of approximately 38.6%[43] - The total liabilities amounted to ¥50,769,042.72, while total equity reached ¥357,672,867.35, indicating a strong equity position relative to liabilities[47] Shareholder Information - The total number of ordinary shares at the end of the period was 55,960,000, with 14,228 shareholders[24] - The largest shareholder, Yan Heping, holds 26,623,000 shares, representing 47.58% of total shares[26] - The company plans to repurchase between 279,800 and 559,600 shares at a maximum price of 10 CNY per share, with a total estimated repurchase fund of 2.798 million to 5.596 million CNY[34] - As of September 30, 2022, the company had repurchased 213,000 shares, accounting for 0.3806% of total shares, with a total expenditure of 1,949,402.82 CNY[35] Cash Flow and Investments - Cash flow from operating activities for the first nine months of 2022 was CNY 9,041,301, a decrease of 48% from CNY 17,338,376 in 2021[57] - Total cash and cash equivalents at the end of Q3 2022 amounted to CNY 75,311,962, up from CNY 19,519,772 at the end of Q3 2021[58] - The company raised CNY 136,750,000 through investment in the first nine months of 2022[58] - Cash outflow from investing activities totaled $79,898,275.92, significantly higher than $25,126,878.71 in the prior period[60] - Cash used for the acquisition of fixed assets was $79,598,275.92, compared to $23,926,878.71, indicating a significant increase in capital expenditures[60] Government Support and Subsidies - The company received a government listing reward of CNY 1,500,000, contributing to an increase in other income[19] - The company received government subsidies closely related to its business totaling 5,194,733.78 CNY[22] Research and Development - Research and development expenses for Q3 2022 were ¥2,978,783.04, compared to ¥2,287,664.89 in Q3 2021, showing an increase of approximately 30.2% year-over-year[50] - Research and development expenses for the first nine months of 2022 totaled CNY 7,162,009, an increase of 10% compared to CNY 6,484,226 in 2021[53] Inventory and Contract Liabilities - Inventory increased by 30.98% to CNY 2,878,000 compared to the end of the previous year due to market demand[17] - The company reported a 389.71% increase in contract liabilities, attributed to new product offerings and advance payments from direct sales customers[18] - Inventory rose to CNY 28,685,144.99 as of September 30, 2022, compared to CNY 21,900,686.36 on December 31, 2021, indicating an increase of about 30.9%[41] Legal and Financial Commitments - The company has no outstanding commitments or overdue obligations related to disclosed commitments during the reporting period[36] - There were no significant legal disputes or external guarantees during the reporting period[30] - The company has cleared its bank loans and does not have any assets under mortgage or pledge as of the reporting period end[37]
大禹生物(871970) - 2022 Q3 - 季度财报